Imexpharm Corporation (HOSE: IMP)

Market Cap	6.92T
Revenue (ttm)	2.16T
Net Income (ttm)	229.63B
Shares Out	154.01M
EPS (ttm)	1,490.89
PE Ratio	30.12
Forward PE	22.38
Dividend	454.55 (1.03%)
Ex-Dividend Date	Jul 11, 2024

Volume	92,200
Average Volume	142,380
Open	44,300
Previous Close	44,300
Day's Range	44,300 - 45,000
52-Week Range	26,909 - 56,500
Beta	0.90
RSI	47.77
Earnings Date	Jan 17, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,415
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2023, Imexpharm's revenue was 1.99 trillion, an increase of 21.31% compared to the previous year's 1.64 trillion. Earnings were 254.62 billion, an increase of 38.50%.